For example, the majority of CML is caused by Bcr-Abl fusion protein expression and targeting the aberrant Abl kinase signaling by imatinib shuts down the proliferation signaling [31]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.